Brain blood flow mystery: does metabolic syndrome hit women harder?
NCT ID NCT07218653
First seen Jun 25, 2026 · Last updated Aug 27, 2026 · Updated 5 times
Summary
This early-phase study looks at whether metabolic syndrome reduces brain blood flow more in women than in men. Researchers will use MRI scans and a drug called indomethacin to test this in 72 healthy adults and those with metabolic syndrome. The goal is to understand sex differences in brain health, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Indomethacin
- What this could lead to
- If successful, this study could reveal why metabolic syndrome harms brain blood flow more in women, pointing toward sex-specific prevention or treatment strategies.
- What could go wrong
- This is a very early, small study (72 people) that measures biological signals, not health outcomes. Results may not lead to any direct treatment or apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 72 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria (Healthy Controls): * 18-45 years old * Normal fasting values for blood glucose (less than 100 g/dl) * Normal values for lipids (LDL cholesterol less than 130 mg/dl, triglycerides less than 150 mg/dl) and HDL (men greater than 40, women greater than 50 mg/dl) * Women must have a predictable menstrual cycle. Females will be studied on cycle days 1-7 to minimize sex hormone differences and their potential confounding effects on vascular outcomes. Oral contraceptives are allowed, and women will be studied during their placebo phase. Inclusion Criteria (Participants with Metabolic Syndrome): * 18-45 years old * Meet at least 3 of the 5 ATP MetSyn criteria. These are: 1. Waist circumference greater than 102 cm (males) or 82 cm (females) 2. Triglycerides greater than 150 mg/dL 3. HDL cholesterol less than 40 mg/dL (males) or 50 mg/dL (females) 4. Blood pressure greater than or equal to 130/85 mmHg 5. Fasting plasma glucose greater than 110 mg/dL Exclusion Criteria (Healthy Controls): * Body Mass Index (BMI) greater than or equal to 25 kg/m2 * Blood pressure over 130/80 mmHg * Meeting any of the 5 MetSyn criteria listed above. Exclusion Criteria (all participants): * Current smoker, defined as more than 5 cigarettes over past 30 days * Current diagnosis or history of: * peripheral vascular disease * hepatic disease * renal disease * lung disease * gastrointestinal disorders/bleeding * hematologic disease * stroke * myocardial infarction * coronary heart disease * congestive heart failure * heart surgery * sleep apnea * autoimmune diseases * HIV * traumatic brain injury, concussion, stroke, or seizures * Asthma * Polycystic ovarian syndrome * Type II diabetes * Currently pregnant or breastfeeding * Current musculoskeletal injury * Medication use known to influence cardiovascular function, other than contraceptive hormones. Broadly, the classes of drugs relate to treating blood pressure, diabetes, cholesterol. * Claustrophobia * Lactose intolerance * Magnesium-restricted diet
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Wisconsin
Madison, Wisconsin, 53706, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a weekly weight drug quiet gout attacks?
- Can a Once-Daily form of tacrolimus spare liver transplant patients from side effects?
- Ketogenic diet vs mediterranean diet: which better reshapes metabolism?
- Can tailoring bypass length improve weight loss surgery results?
- Can AI predict your lifespan from a short video?
- Do obese children with autism face different heart risks?